The number of members of the Pharmaceutical Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service will be expanded from around 100 to around 105. It is a policy to strengthen the expertise in evaluating the adequacy of drug treatment benefits by increasing the number of experts recommended by pharmaceutical-related societies by five more. On the 21st, HIRA announced an administrative notice of a partial revision of the committee's operating regulations containing these contents.

This committee is a special committee that makes the final decision on whether or not to apply for benefits and whether the benefits of expanded drugs are appropriate. To that extent, the deci